Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer

Patent metadata

Field	Value
Publication number	US-10869855-B2
Application number	US-202016814403-A
Country	US
Kind code	B2
Filing date	Mar 10, 2020
Priority date	Jul 26, 2012
Publication date	Dec 22, 2020
Grant date	Dec 22, 2020

Abstract

A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, including the step of administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer. In a preferred embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

First claim

What is claimed and desired to be secured by Letters Patent of the United States is:

1. A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, comprising the step of:
administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer, to, in turn, eliminate, modulate, and/or reduce macrophage migration inhibitory factor cytokine and/or its biological activity.

2. The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1 , wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.

3. The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1 , wherein the isothiocyanate functional surfactant comprises a lysine derivative, wherein the lysine derivative comprises an α-nitrogen and a ε-nitrogen, and wherein an alkyl and/or alkanoyl substituent comprising at least approximately 8 carbon atoms is associated with the α-nitrogen, and further wherein at least one isothiocyanate functional group is associated with the ε-nitrogen.

4. The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1 , wherein the isothiocyanate functional surfactant is represented by the following chemical structure:

wherein the protonated form of the surfactant comprises a non-polar moiety (NP) and a polar moiety (P), and wherein at least one isothiocyanate functional group (NCS) is associated with the polar and/or non-polar moiety.

5. The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1 , wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

wherein R 1 comprises an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer; wherein R 2 comprises NCS; and wherein R 3 -R 5 are the same or different and comprise H; OH; an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer with the proviso that at least one of R 3 -R 5 comprise an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 8 to approximately 25 carbon atom(s).

6. The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1 , wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

wherein R 1 is selected from the group consisting of an alkyl group containing 1 to 25 carbon atom(s); wherein R 2 is selected from the group consisting of NCS; and wherein R 3 -R 5 are each independently selected from the group consisting of H; OH; and an alkyl, and alkanoyl group containing 1 to 25 carbon atom(s) with the proviso that at least one of R 3 -R 5 is selected from the group consisting of an alkyl, and alkanoyl, group containing 8 to 25 carbon atoms.

7. The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1 , wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

wherein X comprises an integer ranging from approximately 1 to approximately 25, and wherein Y comprises an integer ranging from approximately 6 to approximately 25.

8. The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1 , wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

9. The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1 , wherein the protonated form of the isothiocyanate functional surfactant is represented by at least one of the following chemical structures:

10. The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1 , wherein the isothiocyanate functional surfactant is represented by the following chemical structure:

wherein R 1 comprises an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer; wherein R 2 comprises NCS; wherein R 3 -R 5 are the same or different and comprise H; OH; an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer with the proviso that at least one of R 3 -R 5 comprise an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 8 to approximately 25 carbon atom(s), wherein X comprises a counter cation such as, but not limited to, alkali metals, alkaline earth metals, transition metals, s-block metals, d-block metals, p-block metals, NZ 4 +, wherein Z comprises, H, R 6 , OR 6 , and wherein R 6 comprises an alkyl, cycloalkyl, polycycloa

Assignees

• Silver Michael E
• The William M Yarbrough Found

Inventors

• Silver Michael E

Classifications

• A61K31/26 Primary

  Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters · CPC title

• A61K31/198

  Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) · CPC title

• A61K9/0014

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title

• A61K9/06

  Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} · CPC title

• A61K31/195

  having an amino group · CPC title